Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-08
2006-08-08
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S226800, C514S230500, C514S255050, C514S300000, C514S314000, C514S368000, C514S375000, C514S405000, C514S456000, C514S434000, C544S091000, C544S048000, C544S405000, C546S275700, C546S121000, C546S167000, C546S173000, C546S176000, C546S122000, C549S360000, C549S218000, C549S315000
Reexamination Certificate
active
07087626
ABSTRACT:
Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (I) is a four, five, or six membered saturated ring and X is C, O or S
REFERENCES:
patent: 5358947 (1994-10-01), Venkatesan
patent: 5670503 (1997-09-01), Kawai et al.
patent: 0 666 079 (1995-08-01), None
patent: 0 923 929 (1999-06-01), None
patent: 0 531 901 (1993-03-01), None
patent: WO 97 35551 (1997-10-01), None
patent: WO 98 52940 (1998-11-01), None
patent: WO 99 58128 (1999-11-01), None
patent: WO 00 61576 (2000-10-01), None
patent: WO 01 16138 (2001-03-01), None
patent: WO 01 72737 (2001-10-01), None
patent: WO 00 44743 (2001-11-01), None
patent: WO 02 16359 (2002-02-01), None
patent: WO 02 066462 (2002-08-01), None
patent: WO 02/034716 (2004-05-01), None
patent: WO 04/106604 (2004-06-01), None
XP-002210048;Effect of FR167653, a Cytokine Suppressive Agent, on Endotoxin-Induced Disseminated Intravascular Coagulation; Nobuchika Yamamotot, et al.; European Journal of Pharmacology 314; 1996; pp. 137-142.
XP-001096045;Effect of FR143430, a Novel Cytokine Suppressive Agent, on Adenocarcinoma Colon-26—Induced Cachexia in Mice; Nobuchika Yamamoto, et al; Anticancer Research 18; 1998; pp. 139-1444.
XP-001097427;Further Investigations on the Antiinflammatory Actvity of Some2-Phenylpyrozolo[1,5-a] Pyrimidine Compounds; R. Pirisino, et al; II Farmaco—Ed. Sci.; vol. 36, Fasc. 8; pp. 682-691.
XP-001097437;Pharmacological Activity of Some Pyrazolo[1,5-a] Pyrimidines; R. Pirisino; II Farmaco—Ec. Sc.; vol. 34—Fasc. 9; pp. 802-807.
Discovery of FR166124, A Novel Water-Soluble Pyrazolo-[1,5-a] Pyridine Adenosine A1Receptor Antagonist; Satour Kuroda, et al.; Bioorganic & Medicinal Chemistry Letters 9 (1999); pp. 1979-1984.
Beight Douglas Wade
DeCollo Todd Vincent
Godfrey Alexander Glenn
Goodson Jr. Theodore
Li Hong-Yu
Eli Lilly and Company
Sayles Michael J.
Seaman D. Margaret
LandOfFree
Pyrrole derivatives as pharmaceutical agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrole derivatives as pharmaceutical agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrole derivatives as pharmaceutical agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3627499